News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aduro Biotech Announces Completion of Enrollment in Phase 2 Clinical Trial


11/29/2012 9:42:24 AM

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. announces completion of enrollment in the Phase 2 clinical trial of the sequential administration of two cancer vaccines, Aduro’s CRS-207 and GVAX Pancreas Cancer Vaccine, in patients with metastatic pancreatic cancer (ClinicalTrials.gov Identifier: NCT01417000). Enrollment was completed eight months ahead of schedule. “We believe the rate of enrollment demonstrates significant interest in this vaccine treatment from our clinical investigators and their patients and reflects the high-quality work and dedication of our clinical trial sites,” said Dr. Dirk Brockstedt, Senior Vice President of Research and Development at Aduro.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES